The U.S. Food and Drug Administration (FDA) has approved the expansion of two dosing regimens (once weekly and twice weekly) for the treatment of patients with relapsed or refractory multiple myeloma (R/R-MM) who have received 1-3 courses of treatment. The two drugs have shown their effectiveness in combination in the treatment of refractory myeloma.
Multiple myeloma is a blood cancer characterized by remissions and relapses. The prognosis of patients worsens with each relapse. As the use of first-line immunomodulatory drug therapies continues to increase, the number of patients treated with these drugs is likely to increase over time. This creates a need for effective treatment options for relapse. "Despite continued progress in the treatment of multiple myeloma, the disease remains incurable and is particularly challenging for patients who relapse or are refractory to existing treatments," said Dr. Carolyn, M.D., Director of Clinical Research for Hematologic Malignancies and Professor of Clinical Medicine. "As a clinician, choosing this option means we can now combine two effective targeted drugs in a new immunomodulatory drug-free triple therapy that has demonstrated deep and durable responses in relapsed patients."
Sodium sulfobutyl-β-cyclodextrin (SBE-β-CD) is a derivative of β-CD with a negatively charged side chain. It has a special effect on positively charged drugs. The inclusion of hydrophobic drugs can improve the water solubility of the drug itself, increase the absorption of the drug in the human body, improve stability, etc. In addition, it can well include drug molecules to form non-covalent complexes, thereby improving the safety of drugs, reducing nephrotoxicity, alleviating drug hemolysis, controlling drug release rate, and masking bad odors. SBE-β-CD is suitable for injection, oral, nasal and ocular medications, and has special affinity and inclusion properties for nitrogen-containing drugs.
